Olon announces the creation of a major center of research and development in Italy

Olon announces the creation of a major center of research and development in Italy, that will give rise to an innovative global R&D model



“The Italian R&D hub will be an international center of excellence” commented Paolo Tubertini, Olon Group CEO. “This investment is a springboard for future growth prospects guided by a clear strategic vision: innovation is our competitive edge”

Leading API supplier Olon has today announced a €10-million investment for the creation of its international research and development hub, which will cover a huge area within its site in Rodano (Milan), one of the largest in the Group’s network and already highly strategic in terms of expertise in advanced manufacturing processes, high containment technologies, and knowledge applied to process development.

Construction work will get underway in May 2022 and the center will be completed, and therefore operative, in the second quarter of 2023.

The new hub represents growth in terms of people, expertise and skills, with the strategic objective of boosting internal know-how. Based on integrated data systems, this know-how will enable the company to scale up products faster and to achieve highly flexible and reliable tech transfer from one site to another.

It will also facilitate the development of new molecules and innovative synthesis methods and, lastly, help the company attain more competitive process safety standards, thus increasing the safety of plants, constant product quality and ensuring business continuity.

The centre will house a number of different areas, each one dedicated to a specific field of application. The hub will include a laboratory for process safety and research into scale-up and transfer processes. It will also have an analytical R&D area, which will broaden expertise for the development of new synthesis methods and new APIs, from the early phase.

Last but not least, there will be a process development laboratory with a team focusing on the development of advanced processes.

All competencies will be interlinked, complementing each other, on the basis of a continuous exchange and cross fertilization model, not only within the new hub but also with the other Olon R&D centers around the world.

“Our vision is not limited to a major expansion of R&D, which is already a fundamental competitive asset for the Group today. We also aim to link the new hub up to all the other R&D centers in order to build a network of medium-sized labs that can absorb the high level of specialization and know-how of technologies specific to one site, transferring them to another.

The knowledge, experience and data will be shared and exchanged, enabling application across Olon’s entire global manufacturing network.” explained Giorgio Bertolini, Senior Vice President R&D at Olon Group.

This means that each and every Olon site will benefit from the best global expertise within the Group, no matter where they are based, supporting new process development or problem-solving.”

The project involves the creation of laboratories with teams focusing on new technologies, or new technological applications, to develop innovative and highly sustainable processes for industrial production.

In particular, Olon is focusing on the introduction of continuous manufacturing, biocatalysis and photochemistry.

Many of these research projects” continued Bertolini, “will be carried out in partnership with the most prestigious Italian and foreign universities, with which we already have well-established partnerships that will be strengthened even further thanks to the new center.

The Italian R&D hub will be an international center of excellence in the pharmaceutical landscape.” commented Paolo Tubertini, Olon Group CEO.

This investment is a springboard for future growth prospects guided by a clear strategic vision: innovation is our competitive edge in the CDMO and Generic API market. And that is why we invest in research: we are an Italian Group, boasting the highest standards of quality, safety and reliability in the world.”


Latest updates from the pharma world

Health&Biotech Accelerator | Deloitte Officine Innovazione

The ultimate goal of the Health&BioTech Accelerator is to identify the most innovative companies globally that meet the innovation goals that the life sciences field is heading for.

ISPE Summer Night 2023

The 2023 edition of the event, which took place on 28 June at the Mudec – Museum of Cultures of Milan, was dedicated to digitization and automation in the pharmaceutical sector

Trends for the future of the pharmaceutical manufacturing

It’s now mandatory the full implementation of the Industry 4.0 paradigm.